semaglutide cardiovascular outcomes news today 🚨 Breaking News: Real-World Data Comparing Semaglutide and Tirzepatide on Cardiovascular Outcomes

Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial - Nanna - 2025 - Diabetes, Obesity and Metabolism

22.62

★★★★☆4.8 (126)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

24.40

★★★★★4.9 (98)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

23.06

★★★★★5.0 (157)

Wegovy lowers cardiovascular risk for adults with obesity at risk for heart disease

21.35

★★★★★4.7 (84)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

24.81

★★★★★4.9 (203)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

21.77

★★★★★5.0 (176)

Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies

29.19

★★★★★4.8 (132)